Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology
- PMID: 33208748
- PMCID: PMC7676231
- DOI: 10.1038/s41467-020-19589-w
Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology
Erratum in
-
Author Correction: Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology.Nat Commun. 2020 Dec 21;11(1):6448. doi: 10.1038/s41467-020-20412-9. Nat Commun. 2020. PMID: 33349634 Free PMC article. No abstract available.
Abstract
Microbiota-host-diet interactions contribute to the development of metabolic diseases. Imidazole propionate is a novel microbially produced metabolite from histidine, which impairs glucose metabolism. Here, we show that subjects with prediabetes and diabetes in the MetaCardis cohort from three European countries have elevated serum imidazole propionate levels. Furthermore, imidazole propionate levels were increased in subjects with low bacterial gene richness and Bacteroides 2 enterotype, which have previously been associated with obesity. The Bacteroides 2 enterotype was also associated with increased abundance of the genes involved in imidazole propionate biosynthesis from dietary histidine. Since patients and controls did not differ in their histidine dietary intake, the elevated levels of imidazole propionate in type 2 diabetes likely reflects altered microbial metabolism of histidine, rather than histidine intake per se. Thus the microbiota may contribute to type 2 diabetes by generating imidazole propionate that can modulate host inflammation and metabolism.
Conflict of interest statement
F.B. is shareholder in Implexion pharma AB. K.C. is a consultant for Danone Research and LNC therapeutics for work unassociated with the present study. K.C. has held a collaborative research contract with Danone Research in the context of MetaCardis project. M.B. received lecture and/or consultancy fees from AstraZeneca, Boehringer-Ingelheim, Lilly, Novo Nordisk, Novartis and Sanofi. The remaining authors do not report any competing interests.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
